KALY - Kali-Extracts Announces Second Bidder On Its Cannabis Biopharmaceutical Technology Valued At $50 Million
November 08 2019 - 10:02AM
InvestorsHub NewsWire
KALY – Kali-Extracts Announces
Second Bidder On Its Cannabis Biopharmaceutical Technology Valued
At $50 Million
Dallas, TX --
November 8, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc.
(Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today announced a second party has approached
the company to express interest in acquiring KALY’s U.S. Patented
Cannabis Extraction Process and related biopharmaceutical
technology has valued the technology at $50 million. KALY
recently announced entering into discussions with a first investor
to explore a possible sale of KALY’s cannabis biopharmaceutical
technology. The first investor valued the technology at $50
million. KALY management considers the valuation consistent
with Goldman Small Cap Research’s recent valuation,
but management maintains a position that the valuation still does
not reflect the full potential of its intellectual property.
The second party expressing interest has not yet communicated the
value it places on KALY’s U.S. Patented Cannabis Extraction Process
and related biopharmaceutical technology. KALY management
indicates it is only entertaining opportunities where KALY
management remains involve in the ongoing development of the
cannabis biopharmaceutical technology and where KALY maintains
rights to the patent in support of its ongoing edible and beverage
business as well as in support of its ongoing hemp farming CBD
extraction business.
KALY’s
intellectual property portfolio contains a deep pipeline of
cannabinoid product candidates including four distinct compounds
listed here:
Chronic Obstructive Pulmonary
Disease (COPD) - The
market for COPD treatment is anticipated to reach $14 billion by
2025;
Type 2
Diabetes - The market for
Type 2 Diabetes is expected to be a $64 billion market by
2026;
Cancer Pain
Management - The overall
pain management treatment market is anticipated to reach $83
billion by 2024, and
Epilepsy
- The market for epilepsy treatment is
anticipated to reach $9 billion by 2022.
In conjunction with the research already conducted
and the next phase of research now moving forward, KALY recently
filed for a new patent application specifically on its formulation
for symptoms associated with COPD and other similar respiratory
conditions. KALY also filed for a trademark
on the name RespRx as the brand name for its CBD
formulation to treat the symptoms associated with COPD and other
similar respiratory conditions. The market
for COPD treatment is anticipated to reach $14 billion by
2025.
In addition to KALY’s ongoing efforts to develop
prescription therapies, KALY has initiated a program to certify its
proprietary CBD extracts derived from KALY’s U.S. Patented
Extraction Process as an Over-The-Counter (OTC) drug under the
requirements prescribed by the U.S. Food and Drug
Administration.
Since the last biopharmaceuticals strategy update,
KALY has made substantial strides. KALY has since engaged
with a major university to initiate a next round of evaluations and
testing of its COPD treatment. The university program is
anticipated to kickoff soon and the company plans to issue periodic
updates as the program proceeds.
KALY has also made recent progress in advancing the
development of its other treatments. The advances have been
made possible by new partnerships. Announcements about the
new partnerships are coming soon.
To stay abreast
of the latest developments and learn more about the company visit
https://www.kali-extracts.com/.
This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and as such, may involve risks and uncertainties.
These forward looking statements relate to, amongst other things,
current expectation of the business environment in which the
company operates, potential future performance, projections of
future performance and the perceived opportunities in the market.
The company's actual performance, results and achievements may
differ materially from the expressed or implied in such
forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214)
210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2023 to Sep 2024